Actively Recruiting
Development of a Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas: Protocol to Obtain Tumour Material From Patients With STS
Led by The Netherlands Cancer Institute · Updated on 2024-06-07
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
The Netherlands Cancer Institute
Lead Sponsor
K
KU Leuven
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are developing a platform to study soft tissue sarcomas (STS) using patient-derived xenografts (PDX) and 2D/3D cell cultures. This research addresses the challenge that current preoperative radiotherapy and systemic treatments are not uniformly effective across the diverse sarcoma subtypes. The study aims to better understand the response of different sarcoma types to therapies, which is difficult due to the rarity and variety of the disease. The study involves obtaining tumor material from patients with confirmed intermediate to high grade STS through a single tumor biopsy or tumor sampling during surgery. This fresh tumor material will be used to create PDX models in mice and 2D/3D cell cultures. Researchers will examine the growth and passage possibilities of these models and study their sensitivity to radiotherapy and chemotherapy over set timeframes ranging from weeks to two years. Participants will provide consent and undergo tumor biopsy or surgery for tissue collection. The study will track the success rate of tumor material implantation in mice and the development of cell culture models. These models will serve as tools for future research on anti-sarcoma therapies. Safety and adherence to follow-up are monitored to ensure reliable data. The total study duration includes short-term assessments and longer-term observation up to two years.
CONDITIONS
Brief Title
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of (non-) metastatic intermediate to high grade soft tissue sarcoma
- Local recurrences are allowed
- Age 18 years or older
- Able and willing to undergo tumour biopsies or tumour sampling during surgery
- Sarcoma location allows safe biopsy or surgery
- Written informed consent provided
You will not qualify if you...
- Known coagulation disorder or use of anticoagulant medication that may interfere with safe biopsy, as determined by physician and radiologist
- Psychological, familial, sociological, or geographical conditions that may hinder compliance with study protocol and follow-up schedule
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure
Participants undergo a tumor biopsy to obtain tumour material for research.
1 visit (in-person)
Duration - Up to 2 years
Tumour material obtained from biopsy is used to develop Patient Derived Xenografts (PDX) and 2D/3D cell cultures for translational research.
No additional participant visits required
Trial Site Locations
Total: 1 location
1
Netherlands Cancer Institute
Amsterdam, Netherlands, 1066CX
Actively Recruiting
Research Team
R
Rick Haas, MD, PhD
A
Astrid Scholten, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here